MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Nocturnal Polyuria in Parkinson’s Disease

    M. Smith, G. Portlock, A. Cullen, M. Drake, Y. Ben-Shlomo, E. Henderson (Bristol, United Kingdom)

    Objective: To characterise the prevalence of nocturnal polyuria in a cohort of people with Parkinson’s disease (PD) with lower urinary tract symptoms. Background: Lower urinary…
  • 2022 International Congress

    MRI to investigate cerebrovascular changes in Parkinson’s disease

    D. Nolan, D. Myall, C. Morgan, R. Shoorangiz, L. Livingston, S. Grenfell, T. Pitcher, M. Macaskill, K-L. Horne, C. Le Heron, S. Marsh, J. Dalrymple-Alford, T. Anderson, T. Melzr (Christchurch, New Zealand)

    Objective: To determine the value of MRI-derived cerebrovascular metrics and their relationship with global cognitive impairment in Parkinson’s disease (PD). Background: Cognitive impairment is a…
  • 2022 International Congress

    Sex-specific factor analysis-derived profile of neuropsychiatric symptoms predicting dementia conversion in Parkinson’s disease

    Y. Lee, SW. Kang, SH. Yoon, K. Baik, HK. Na, YH. Sohn, PH. Lee (Seoul, Republic of Korea)

    Objective: Neuropsychiatric symptoms (NPS) are closely associated with cognitive decline in patients with Parkinson’s disease (PD). We investigated which baseline profile of NPS predicts the…
  • 2022 International Congress

    Remote identification of early, sensor-based markers of Parkinson’s Disease using participants’ smartphones: The Parkinson Progression Marker Initiative Digital sub-study

    W. Popp, K. Taylor, T. Perumal, C. Tanner, A. Siderowf, L. Chahine, E. Brown, T. Simuni, T. Foroud, T. Kustermann, G. Pagano, H. Svoboda, M. Lindemann, K. Marek (Basel, Switzerland)

    Objective: To summarize the design of the Parkinson’s Progression Markers Initiative (PPMI) Digital sub-study. The study objective is to identify the earliest signs and symptoms…
  • 2022 International Congress

    What, when and how should the information on iRBD and risk of Parkinson’s disease and related conditions be communicated?

    H. Chohan, C. Simonet, A. Gill, A. Schrag, A. Noyce, L. Pérez-Carbonell (London, United Kingdom)

    Objective: To investigate what, when and how patients with iRBD would like to receive information regarding the potential future implications of having iRBD, once diagnosis…
  • 2022 International Congress

    Patterns of early-phase 18F-FP-CIT PET images and the risk of dementia conversion in Parkinson’s disease

    S. Chung, P. Lee, Y. Kim, Y. Sohn (Yongin-si, Republic of Korea)

    Objective: This study aims to investigate the prognostic relevance of the patterns of early-phase 18F-fluorinated N-3-fluoropropyl-2-beta-carboxymethoxy-3-beta-(4-iodophenyl) nortropane (18F-FP-CIT) positron emission tomography (PET) images in patients…
  • 2022 International Congress

    Central olfactory structure atrophy is linked to synucleinopathy conversion in idiopathic REM sleep behavior disorder

    KA. Woo, JY. Lee, H. Kim, YK. Kim (Seoul, Republic of Korea)

    Objective: We hypothesized that early structural changes in the brain olfactory relevant structures may help early identification of those at risk of future disease conversion…
  • 2022 International Congress

    Novel strategies based on sensory electrical stimulation to manage tremor in Parkinson’s disease. A pilot study.

    C. Montero Pardo, M. González Sánchez, A. Pascual Valdunciel, J. Sánchez Pérez, J. Camilo Moreno, F. Oliveira Barroso, F. Grandas, J. Luis Pons (Madrid, Spain)

    Objective: Tremor can be a disabling motor symptom in patients with Parkinson´s disease (PD) and in some patients is refractory to medication. Here we present…
  • 2022 International Congress

    Gait abnormalities relate to increased extracellular water in the substantia nigra in Parkinson’s disease patients

    M. Bange, G. Gonzalez-Escamilla, N. Lang, A. Radetz, H. Ding, D. Herz, W. Schöllhorn, M. Muthuraman, S. Groppa (Mainz, Germany)

    Objective: The aim of this study was to investigate the role of substantia nigra microstructural integrity in parkinsonian gait impairments. Background: Gait impairments are common…
  • 2022 International Congress

    APEG-PCL Nanoparticles Containing Rifampicin Target Dopaminergic Neurons to reduce α-synuclein aggregation

    D. Lin, K. Huang (Shenzhen, China)

    Objective: There were accumulating evidence proving that rifampicin could protect neurons from apoptosis in Parkinson's disease in-vitro model by regulating SUMO modification of α-synuclein. However,…
  • « Previous Page
  • 1
  • …
  • 382
  • 383
  • 384
  • 385
  • 386
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • #25062 (not found)
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley